In fact, we and others reported that clinical vaccination trials in gastric or breast cancer patients using DCs pulsed with HER-2 peptides confirmed the fact that vaccination with HER-2 peptides is immunogenic, and that HER-2 could be a good target for immunotherapy (Disis et al, 1999; Kono et al, 2002c). The gene discussed is ERBB2; the disease is breast cancer.